Belimumab Holds Lupus Organ Damage Near Zero Over 8 Years in Landmark Long-Term Study
Pooled data from 1,299 SLE patients show belimumab nearly halts organ damage accrual and slashes steroid use over 8 years.
Summary
Lupus can quietly damage the kidneys, heart, brain and other organs, and long-term steroid use adds to that damage. This analysis pooled three long-term extension studies of 1,299 adults with lupus who received belimumab, a drug that dials down overactive B cells, on top of standard care. Over 8 years, average organ damage scores rose by no more than 0.3 points, and about 79% of patients showed no increase in damage at all. The share of patients on low-dose steroids (7.5 mg/day or less of prednisone-equivalent) rose from 29% in year 1 to 74% in year 8. Safety was tracked for up to 13 years, and no new safety concerns emerged. Infections were common, as expected. Because the studies had no control group, the results show association rather than proof.
Detailed Summary
Systemic lupus erythematosus (SLE) is a lifelong autoimmune disease. Irreversible organ damage appears in up to 22% of patients within a year of diagnosis, 40-50% within five years, and 86% within 25 years. Damage is driven by uncontrolled disease activity and cumulative glucocorticoid exposure, and each one-point rise in the damage index (SDI) is linked to a 34% higher mortality risk. Long-term data on therapies that can limit both flares and steroid dependence are therefore valuable.
This post hoc analysis pooled three open-label long-term extension (LTE) studies (BEL112233, BEL112234, BEL112626) that followed patients from the phase 2 LBSL02 trial and the phase 3 BLISS-52 and BLISS-76 trials. Of 1,304 enrolled patients, 1,299 received at least one dose of belimumab (10 mg/kg intravenously every 28 days) plus standard therapy. Participants were 94% female, with a mean age of 39.7 years and disease duration of 7.2 years. Baseline SELENA-SLEDAI averaged 8.2 and SDI 0.7. Cumulative exposure reached 7,236 patient-years.
On medication use, 94.1% of patients took glucocorticoids at some point, 74.6% took antimalarials, and 56.4% took immunosuppressants. Steroid and immunosuppressant use declined over time while antimalarial use stayed stable. The proportion of patients at or below 7.5 mg/day prednisone-equivalent rose from 29% in year 1 to 74% in year 8. Patients receiving no steroids rose from 12.9% to 32.5%, and those with a maximum daily dose of more than 7.5 to 40 mg fell from 52.9% to 23.7%.
Organ damage accrual was low. Mean SDI changes through year 8 never exceeded 0.3 (SD 0.6) in the full population, the high disease activity subgroup, or the 5-year completers. By year 8, 79%, 76% and 79% of these groups respectively had no SDI change. Most who worsened rose by just one point, and fewer than 1% had a +3 or +4 change in any year. About 85% of 5-year completers had no worsening at year 5. SDI was assessed only in the BLISS-based LTEs (n=1,003).
Safety over up to 13 years was consistent with the known profile. Any adverse event occurred in 97.5% of patients, serious events in 40.4%, and events leading to discontinuation in 10.7%. Infections affected 87.8%, including herpes zoster (10.5%), opportunistic infections (3.4%), and active tuberculosis (0.3%). Infections of special interest occurred at 5.1 per 100 patient-years. Malignancies, including non-melanoma skin cancer, occurred in 3.6%. Depression, suicide or self-injury events were reported in 22.8%, and 21 patients (1.6%) died, with 3 deaths judged possibly drug-related.
Several caveats apply. The analysis was post hoc, open-label and uncontrolled, and it is descriptive and based on observed data, so survivors and responders are overrepresented: only 46.5% of patients completed the LTEs. Steroid tapering was not mandated, and the benchmark of 7.5 mg/day is higher than the current 5 mg/day guideline target. Damage cannot be attributed to belimumab without a comparator, and data after year 8 came largely from a single study.
Key Findings
- Pooled analysis of 1,299 patients (94% female) treated with belimumab plus standard therapy, totaling 7,236 patient-years of exposure
- Patients at or below 7.5 mg/day prednisone-equivalent rose from 29% in year 1 to 74% in year 8; those off steroids rose from 12.9% to 32.5%
- Mean SDI change from baseline never exceeded 0.3 (SD 0.6) through year 8, with similar results in high-disease-activity patients and 5-year completers
- 79% of patients had no increase in SDI by year 8, and fewer than 1% had a +3 or +4 change in any year
- 97.5% had at least one adverse event, 40.4% had a serious adverse event, and only 10.7% discontinued because of an adverse event over up to 13 years
- Infections of special interest occurred at 5.1 per 100 patient-years, including herpes zoster (10.5% of patients) and active tuberculosis (0.3%)
- Malignancies occurred in 3.6% of patients and 21 patients (1.6%) died, with 3 deaths considered possibly drug-related
Methodology
This was a post hoc pooled analysis of three open-label LTE studies following the LBSL02, BLISS-52 and BLISS-76 parent trials. All 1,299 treated patients received belimumab 10 mg/kg IV every 28 days plus standard therapy, with no control arm. Analyses were descriptive and based on observed data, using a single belimumab group relative to baseline. Organ damage (SDI, assessed every 48 weeks) was available only for the BLISS-based LTEs, in the full population, a high-disease-activity subgroup and 5-year completers. Safety was followed for up to 13 years and reported as incidence and events per 100 patient-years.
Study Limitations
The analysis was post hoc, open-label and uncontrolled, so organ damage prevention and steroid sparing cannot be causally attributed to belimumab. Attrition was substantial (only 46.5% completed the LTEs), which may favor patients who tolerated or benefited from treatment, and SDI data were limited to the BLISS-based studies. The 7.5 mg/day steroid threshold is above current guideline targets of 5 mg/day or less, and funding and conflict-of-interest details were not visible in the supplied text, so readers should check the disclosures (the LTE program was a manufacturer-run development program).
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
